Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open‐label pilot study
Open accessThe DOI matches its Crossref record.
Abstract
Background: Mast cells isolated from the colonic mucosa in active ulcerative colitis appear to be partially degranulated, suggesting the release of tryptase. Aim: To investigate the safety and activity of APC 2059, a highly specific tryptase inhibitor, in the treatment of ulcerative colitis. Methods: This was an open‐label, Phase 2, multicentre pilot study in patients with mildly to moderately active ulcerative colitis, with a disease activity index of 6–9 on a 12‐point scale. Fifty‐six adults received 20 mg APC 2059 subcutaneously twice daily and 53 completed 28 days of treatment. The primary end‐point was response, defined as a final disease activity index of ≤ 3. Supplementary analyses were also performed. Results: Sixteen (29%) of 56 patients responded. Five (9%) showed complete remission (disease activity index=0). Twenty‐seven (49%) improved, with a final disease activity index of ≤ 3 or a four‐point reduction. Improvement or normalization in each category of the disease activity index was as follows: stool frequency, 64%; bleeding, 64%; endoscopy, 50%; physicians' rating, 63%. There were no significant relationships between outcome and pharmacokinetics. The most common adverse events were related to the injection site (32.1%). Conclusions: In this pilot study, the tryptase inhibitor APC 2059 was safe and there was evidence of activity in the treatment of ulcerative colitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Protease-Activated Receptors: Contribution to Physiology and Disease
OSSOVSKAYA, V. S., & BUNNETT, N. W. (2004) · Physiological Reviews · doi:10.1152/physrev.00028.2003 · Cited by 1,078
Mast cell tryptases and chymases in inflammation and host defense.
Caughey, G. H. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00509.x · Cited by 442
“ulcerative colitis, a condition in which tryptase inhibitors may be beneficial (88).”
Induction of Intestinal Inflammation in Mouse by Activation of Proteinase-Activated Receptor-2
Cenac, N., Coelho, A.-M., Nguyen, C., Compton, S., Andrade-Gordon, P., MacNaughton, W. K., Wallace, J. L., Hollenberg, M. D., Bunnett, N. W., Garcia-Villar, R., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64466-5 · Cited by 378
Pejler, G., Åbrink, M., Ringvall, M., & Wernersson, S. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)95006-3 · Cited by 320
The role of mast cells in functional GI disorders
Wouters, M. M., Vicario, M., & Santos, J. (2016) · Gut · doi:10.1136/gutjnl-2015-309151 · Cited by 308
“104 105 Our group has recently fi nished an open trial (awaiting publication) and a consecutive double-blind, placebo-controlled, clinical assay, with prolonged (6 months) oral administration of DSCG, with promising results in the control of main clinical manifestations in patients with IBS-D (…”
Metadata
- Authors
- Tremaine, W. J., Brzezinski, A., Katz, J. A., Wolf, D. C., Fleming, T. J., Mordenti, J., Strenkoski‐Nix, L. C., Kurth, M. C., & THE AXYS ULCERATIVE COLITIS STUDY GROUP
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2002-03
- Volume
- 16
- Issue
- 3
- Pages
- 407-413
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1991409953
- Cited by
- 90
- References
- 0
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open‐label pilot study. https://app.cochat.ai/papers/10.1046/j.1365-2036.2002.01194.x
- The paper
- Tremaine, W. J., Brzezinski, A., Katz, J. A., Wolf, D. C., Fleming, T. J., Mordenti, J., Strenkoski‐Nix, L. C., Kurth, M. C., & THE AXYS ULCERATIVE COLITIS STUDY GROUP. (2002). Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open‐label pilot study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2002.01194.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.